Navigation Links
Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations
Date:10/14/2010

ts that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facilities that produce our products or production or regulatory problems with either third party manufacturers or API suppliers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation, including domestic and foreign health care reform, affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; our ability to realize the anticipated opportunities from our acquisition of the global branded pharmaceuticals business from The Procter and Gamble Company; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2009, and from time-to-time in our other investor communications.

We caution you that the foregoing list of important factors is not exclusive.  In addition,
'/>"/>

SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic
2. Warner Chilcott Announces FDA Approval of Next Generation Actonel
3. Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering
4. Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex®
5. Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
6. Warner Chilcott Announces $500 Million Senior Notes Offering in Connection With Agreement to Acquire U.S. Rights to Enablex®
7. Warner Chilcott to Present at UBS Global Life Sciences Conference
8. Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
9. Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance
10. Warner Chilcott Announces Earnings Release Date and Conference Call for Second Quarter 2010 Financial Results
11. Warner Chilcott Announces 3-Month Extension of PDUFA Date on Next Generation Actonel Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... -- Thousands of people will peacefully demonstrate their frustration ... epidemic at dozens of rallies across the country today. ... the United States has experienced skyrocketing rates ... heroin, yet the President has never once spoken publicly ... to President Obama , rally organizers compared his failure ...
(Date:8/31/2015)... , Aug. 31, 2015  Daktari Diagnostics today announced a ... United States and Canada , ... The deal, worth up to $8.5 million over the next ... clinical validation and regulatory approval of Daktari,s HCV test. ... point-of-care instrument that can detect low levels of virus directly ...
(Date:8/31/2015)... , Aug. 31, 2015 With increasing ... is experiencing a rise in active partnerships. The ... underdeveloped nations to quantitate CD4 cell markers in ... - http://photos.prnewswire.com/prnh/20150831/262206LOGO New ... Global Flow Cytometry Market ( http://www.frost.com/nf0e ), finds ...
Breaking Medicine Technology:Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4
... ViroPharma Incorporated (Nasdaq: VPHM ) today ... Centralized Marketing Authorization for Cinryze® (C1 inhibitor [human]) ... for routine prevention, pre-procedure prevention and acute treatment ... self administration option for appropriately trained patients included ...
... Texas, June 15, 2011 Two clinical trial studies authored by ... United Network of US Oncology have been selected to be ... July 29-30 in Miami and August 5-6 in Seattle. ... its 47th Annual Meeting June 3-7 at McCormick Place in Chicago. ...
Cached Medicine Technology:ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE) 2ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE) 3ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE) 4ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE) 5ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE) 6Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians 2Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians 3Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians 4
(Date:8/31/2015)... ... August 31, 2015 , ... ... at the 16th Innovations in Healthcare(SM) Awards Event , on October 21, ... (ABL) Organization , recognizes innovative organizations and individuals who are dramatically reducing the ...
(Date:8/31/2015)... , ... August 31, 2015 , ... The dental implant ... according the American Academy of Implant Dentistry. (See Press Room ) More than ... require an implant procedure. With the increasing demand for dental implants, the National Association ...
(Date:8/31/2015)... , ... August 31, 2015 , ... Three Bakers Gluten ... and retailers with even more relevant and easy-to-find information on their offering of gluten-free ... website has always been an important way for us to share information about our ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dad Phil, ... ribbon-cutting ceremony on Aug. 26, generously hosted by the Collinsville Chamber of Commerce, ... AdvantaClean’s National Call Center and website since Aug. 17. , The Greens have ...
(Date:8/31/2015)... ... 2015 , ... Finnleo is pleased to announce another in a ... of extensive engineering and design of our newest sauna model, the Terrace combines high ... offered at a very attractive price-point. , Before outdoor saunas were a dream ...
Breaking Medicine News(10 mins):Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8Health News:Dental Association Raises Awareness as Implant Industry Grows 2Health News:Dental Association Raises Awareness as Implant Industry Grows 3Health News:Dental Association Raises Awareness as Implant Industry Grows 4Health News:Three Bakers Gluten Free Bakery Announces Launch of New Website 2Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:Say “Hello” to the Brand New Finnleo Terrace Outdoor Saunas 2
... team up to make food fun,for those with diabetes, ... the daily decisions they make about food can have ... (ADA), together,with The HealthCentral Network,s FoodFit.com, launched Diabetes Foodsmart,today, ... to food for those,with diabetes., Based on the ...
... with 20 percent of all lung malignancies, scientists say ... appear to work together are associated with 20 percent of ... lung development, researchers report. , Understanding how these genes mesh ... according to the report in this week,s issue of the ...
... IRVINE, Calif., Oct. 9 Spectrum,Pharmaceuticals, Inc., (Nasdaq: ... of the Company on Wednesday, October 10, 2007, at ... at the Palace Hotel in San,Francisco, California. Spectrum,s presentation ... live webcast of Spectrum,s presentation will be available at, ...
... Two of the three scientists receiving the 2007 Nobel Prize ... Society early in their careers, bringing to 42 the number ... grantees Mario R. Capecchi, Ph.D. of the University of Utah ... are co-winners along with Sir Martin J. Evans of Cardiff ...
... Oct. 9 In light of last week,s,controversy ... seafood for,pregnant women and the announcement from private ... least 12 ounces of fish,and seafood a week, ... in the natural products sector, suggests that private ...
... Roaming Across ... Campuses in North Carolina, RESTON, Virginia, October 9 ... (RTLS), today announced,that it has been selected as the RTLS vendor ... system in the,United States. CHS is using the Ekahau RTLS solution ...
Cached Medicine News:Health News:Healthy Living Made Easy with New Diabetes Foodsmart e-Newsletter 2Health News:Healthy Living Made Easy with New Diabetes Foodsmart e-Newsletter 3Health News:3 New Lung Cancer Genes Identified 2Health News:Spectrum Pharmaceuticals to Present at the Biotechnology Industry Organization Investor Forum 2Health News:Purified Fish Oil Concentrates Offer Solution to Current Seafood Controversy for Pregnant and Breastfeeding Women! 2Health News:Carolinas HealthCare Selects Ekahau for One of Nation's Largest Healthcare System RTLS Deployments 2Health News:Carolinas HealthCare Selects Ekahau for One of Nation's Largest Healthcare System RTLS Deployments 3Health News:Carolinas HealthCare Selects Ekahau for One of Nation's Largest Healthcare System RTLS Deployments 4
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The electrically active helix of CapSureFix Novus lead is designed to extend easily for active fixation and retract for venous passage....
Steroid eluting pacemaker leads...
... family of temporary sensing and pacing leads. ... in temporary pacing leads and improved upon ... use and less traumatic to heart tissue. ... Pacing Lead is designed for temporary atrial ...
Medicine Products: